Lucira Health, Inc.
Lucira Health, Inc. (LHDX): 1 pipeline candidate · ~7 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
6.8 months
D/E 2.11 · 0% dilution
Lead: Preclinical
1 candidate
N/A
N/A
A transparent, data-derived signal for Lucira Health, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$39.8M
Quarterly Burn
$28.2M
Runway
6.8 mo
Revenue
$34.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| combination covid-19 | Preclinical |
Frequently asked questions
How many drug candidates are in Lucira Health, Inc.'s pipeline?
Lucira Health, Inc. (LHDX) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Lucira Health, Inc.'s lead drug candidate?
Lucira Health, Inc.'s most advanced tracked candidate is combination covid-19 (Preclinical) for COVID-19 and influenza.
What is Lucira Health, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Lucira Health, Inc. has approximately 6.8 months of cash runway.
Get the full picture on Lucira Health, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.